研究業績

2026年

論文

• "Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan"
  Mamiya, Hiroaki, Toshiki Fukasawa, and Koji Kawakami
  Journal of Pharmaceutical Policy and Practice 19, 1 (2026).

  • DOI: 10.1080/20523211.2026.2633832.

総説／雑誌記事

• "医薬品の安定供給に関する課題と法改正 ―政策経緯と構造的要因の解明―"
  大矢 恵理，間宮 弘晃，三谷 大地
  医薬品医療機器レギュラトリーサイエンス 57, 1 (2026).

2025年

論文

• "Temporal Trends in the Prescription of Biosimilars and the Status of Switching from Original Biologics to Biosimilars at Individual and Institutional Levels in Japan"
  Minako Matsumoto, Ryosuke Kumazawa, Akiko Ishii-Watabe, Itsuko Horiguchi, Hiroaki Mamiya, Hiroko Shibata, Yoshiro Saito, Motohiko Adomi, Yuta Taniguchi, Jun Komiyama, Ryoko Sakai & Masao Iwagami
  Therapeutic Innovation & Regulatory Science (2025).

  • DOI: https://doi.org/10.1007/s43441-025-00850-7
• "Including Productivity as an Element to Reflect Value of the Treatment: A Systematic Review of Published Health Economic Evaluations"
  Hiroaki Mamiya, Kittima Wattanakamolkul, Nan Li, David Bin-Chia Wu, Mariko Hirozane & Ataru Igarashi
  PharmacoEconomics Open (2025).

  • DOI: https://doi.org/10.1007/s41669-025-00589-9
• "Effects of Reimbursement Add-On Policies on Trastuzumab and Bevacizumab Biosimilar Adoption in a Japanese Oncology Setting"
  Hiroaki Mamiya, Toshiki Fukasawa, Koji Kawakami
  Value in Health Regional Issues 46, 101090 (2025).

  • DOI: 10.1016/j.vhri.2025.101090

総説／雑誌記事

• "医薬品の安定供給のための国内外の施策について"
  間宮弘晃、伊豆津健一
  PHARM TECH JAPAN 41, 05 (2025).